

Instructions & Guidelines

Advancing Understanding. Improving Lives.

Avancer la compréhension. Améliorer la vie.

If YES, then please complete the <u>REB Application</u>, Human Subjects Research Application Form (TAHSN)

 \square No

Retrospective Chart Review Application

If NO, then please complete this form, <u>Retrospective Chart Review Application</u>.

and authorization if these criteria are rachieved without the information; b) is	aiver of consent. Note: The REB may waive the requirement for subject (see also PHIPA (2004) s. 44(3)): a) the research purposes cannot is impracticable to obtain consent; c) the information is used in a manufacture in conducting the research exceeds the public interest ls.	t be nner that
brastogi@waypointcentre.ca. Applica approved, the REB will notify the Prir	with supporting documentation to Bhavya Rastogi, tions normally undergo a delegated review process. Once the submissicipal Investigator (PI) and Health Information Management (HIM) by M with the REB approval letter, REB approved Study proposal and thon.	y email.
SECTION 1A: Principal Investiga	tor Information (Must be Waypoint Staff Member)	
Name:	Telephone #:	
Title	Fax #	
Department:	Email	
_		
Wing/Floor/Room:		
Address Including		
Postal Code		
·		

SECTION 1B: Co-Investigator(s) Information (Attach additional pages if required)							
Names(s)		1.	Telephone #		1.		
		2			2		
Title		2. 1.	Fax	#	2. 1.		
Title		1.	гах	#	1.		
		2.			2.		
Department &		1.	Ema	ıil	1.		
Wing/Floor/R	oom						
4 1 1 Y 1	1.	2.			2.		
Address Include Postal Code	ding	1.					
Postai Code		2.					
		۷.					
				<u>.</u>			
CECTION 10	N. Da4	a Abatua ataw(a) Imfa wwaati	om (A44 mole)			.1\	
		a Abstractor(s) Information Principal Investigator	on (Auach d	Same as Co-l			
Name(s)	1.	Timelpai investigator		Title	1.	.5)	
T (unite(s)	1.				1.		
	2.				2.		
Institution	1.			Telephone #	<i>‡</i> 1.		
Dan auton aut/	2.			Email	2.		
Department/ Division	1.			Email	1.		
Division	2.				2.		
Address	1.				2.		
	2.						
SECTION 2A	: Tvp	e of Data Request					
Diagnosis		Demographic Information		Aggregate			
Other							
		to be extracted from d from Health Records, this	s form MUS	ST be signed by	y the Manag	er, Health Information	
	ords/C	Clinic/Office Files	Electr	onic Database	S	Outside Institutions	
Specify:			Specify:			Specify:	
Other							
Specify:							

SECTION 3: Project Summar	y					
Project Title						
-						
State the rationale,						
objectives and the						
question(s) this study will						
answer?						
Provide study summary						
and outline analyses						
(maximum 250 words)						
*Attach detailed protocol						
separately						
D' 1 11 6'4 6'41						
Risks and benefits of the						
proposed study and how						
will you manage the risks?						
Charify the data to be						
Specify the data to be collected (attach data						
collection form)						
Proposed number of						
Patients/Charts						
Proposed start date of	/ /		Proposed t	ermination date	/	/
project	(DD/MM/YYYY) Proposed termination dat		crimination date	(DD/MM/YYYY)		
Date range of requested	Start date	,		End date	(DD/III	11111)
data under review	Start date	/	/	End date	/	/
(e.g. 22/01/1999 to		,	M/YYYY)		(DD/M	M/YYYY)
22/07/1999)		(22/1/11	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(22/1/1	1,1,1111)
How will this be funded?	Grant		Industry	Internal		☐ No Funding
						Required
	Specify funding	St	oonsor:	Specify fund	ling	1
	source:			source:	C	
	•	-		•		•

Please address the following ethical concerns regarding access to confidential health information. The response to				
	y detailed and complete to allow the REB to determine the merit of the			
investigation and that sufficient	protection is in place to protect the confidentiality and security of the information.			
Incomplete applications will be	returned. All Study Personnel must sign the confidentiality agreement below.			
SECTION 4: Information Protection - Patient Identifying Data				
If personal health information	☐ Yes ☐ No			
is collected, used or disclosed,				
without consent from				
individuals to whom the				
information relates, explain				
why obtaining explicit consent				
would be impractical.				
TT 111 1 4 4 4				
How will relevant patient				
charts be identified?				
Have you almostly developed a	Yes No			
Have you already developed a list of specific patients?	If yes, please indicate how patients were identified:			
ist of specific patients:	if yes, please indicate now patients were identified.			
Will any identifying	Yes No			
information be recorded?	If yes, please justify the necessity for its collection:			
information be recorded.	if yes, please justify the necessity for its concerton.			
Please indicate the type of	Full Name Address Telephone Number			
patient identifying data (check				
all that apply)	☐ Provincial Health Card Number ☐ Social Insurance Number			
	☐ Medical Record Number ☐ Full Date of Birth ☐ Age or Year of Birth			
	☐ Month and Year of Birth ☐ Gender ☐ Discharge date			
	Month and Teal of Birth Gender Discharge date			
	☐ Email addresses ☐ Healthcare Provider e.g. Family Physician, VON Etc.)			
	Other (Specify)			
Will individual identifiers be	Yes No			
removed and data anonymised	If no, please justify:			
once the relevant data is				
collected?				
Will this data be transferred	☐ Yes ☐ No			
external to Waypoint?	Is a Data Sharing Agreement in place with the outside institution?			
	☐ YES ☐ NO ☐ Pending			
	TES NO Tending			
	How will the confidentiality be protected?			
	220 W W 222 00 222 222 222 222 222 222 2			

Is this a Multicentre Study? Yes No If yes, identify the coordinating site and the other sites and indicate the REB approval status: Any anticipated linkage of the data with other existing data? Will the data be reported publicly? (e.g. publication, seminar, conference etc.,) Will the data collected be used Yes No No N/A
Any anticipated linkage of the data with other existing data? Will the data be reported publicly? (e.g. publication, seminar, conference etc.,) Yes No Yes No Yes No Please specify:
Any anticipated linkage of the data with other existing data? Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
data with other existing data? If yes, please provide details and how will the linkage information be treated: Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
data with other existing data? If yes, please provide details and how will the linkage information be treated: Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
data with other existing data? If yes, please provide details and how will the linkage information be treated: Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
data with other existing data? If yes, please provide details and how will the linkage information be treated: Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
data with other existing data? If yes, please provide details and how will the linkage information be treated: Will the data be reported publicly? (e.g. publication, seminar, conference etc.,)
Will the data be reported publicly? (e.g. publication, seminar, conference etc.,) Please specify:
publicly? (e.g. publication, seminar, conference etc.,) Please specify:
publicly? (e.g. publication, seminar, conference etc.,) Please specify:
publicly? (e.g. publication, seminar, conference etc.,) Please specify:
(e.g. publication, seminar, conference etc.,) Please specify:
conference etc.,)
<i>"</i>
Will the data collected be used Yes No N/A
now or in the future for
commercial purposes?
Describe any Conflict of
Interest (such as financial If yes, please provide details:
benefits, share ownership
stock options etc.) by members of the research /
team/institution/ sponsor How will security and
confidentiality of the data be
protected, maintained and
retained?

Confidentiality Agreement:

THE FOLLOWING REPRESENTS THE TERMS AND CONDITIONS UNDER WHICH THE HANDLING OF CONFIDENTIAL INFORMATION FOR THE PROJECT SHALL PROCEED. THESE TERMS AND CONDITIONS HAVE BEEN DRAFTED IN COMPLIANCE WITH THE *PERSONAL HEALTH INFORMATION PROTECTION ACT* AND OTHER PRIVACY LEGISLATIONS.

- 1. All information received or exchanged will be held in strict confidence.
- 2. Information will not be used for any purpose other than for the project for which it was provided. The information will be shared only with those individuals listed on this form, who are working directly on the project, except for authorized oversight of the study. Information use will comply with REB approved conditions, if any.
- 3. No attempt will be made to contact any individual, directly or indirectly, unless the health information custodian first obtains the individual's consent to being contacted (see PHIPA (2004) s. 44(6)e)
- **4.** Information will be kept in a location that is physically secure as per approved research protocol and to which access is given only to the individual(s) listed on this form.
- 5. All direct identifiers will be segregated / stripped from clinical data; a unique study identifier (i.e. a randomly generated or meaningless ID number) will be assigned to each patient record; the Master list linking the ID with identifiable material will be stored in a separate computer file and/or physical location; and the Master list will be locked and password protected.
- **6.** No information will be stored on mobile devices without encryption.
- 7. No information will be released outside the province of Ontario.
- **8.** Data sent or received electronically by the institution will require that the outside individuals/vendors enter into a confidentiality agreement before the data transfer takes place. The "Statement of Confidentiality" form must be signed, witnessed and returned to Clinical Information Services before providing access to any system/data. The "Statement of Confidentiality" form can be obtained from Clinical Information Services.
- **9.** Policies and procedures on the secure retention and secure destruction of information must be in place by the party undertaking the project.
- 10. It is strongly recommended that members of the research team and any individual(s) listed below read the <u>Personal Health Information Protection Act</u>. Part IV, Sec 44(6)-"Compliance by Researcher" <u>http://www.e-laws.gov.on.ca/html/statutes/english/elaws_statutes_04p03_e.htm</u>
- 11. Publication of confidential information requires adherence to the following principles:
 - The institution agrees to allow the publication of the information as it pertains to the project providing that the institution or its practices are not the main focus of the publication.
 - In cases where the publication focuses on the institution, the institution reserves the right to review and approve the use of this information prior to publication.
 - The institution will be acknowledged within any publication as providing the source information in the following fashion: "The authors kindly acknowledge and thank authorities of Waypoint Centre for Mental Health Care for providing source information on health data for use on this research for the year (XXXX) (specify year)".
 - A copy of the publication will be given to the institution.
- **11.** In the event of a potential/suspect/or actual breach of privacy (lost/stolen), the Manager, HIM, Privacy and Risk Management (MHP&RM) will be contacted within 1 business day. In the event of an actual breach, the MHP&RM will also be notified in writing (S44(6)).
- **12.** A breach of institutional policy regarding access to information and protection of privacy may have serious consequences or be just cause for termination of my employment and/or affiliation with the institution.
- **13.** Personal Health Information that can easily identify a patient should not be published. NOTE: any mishandling or unauthorized use of study data will lead to cancellation of REB approval for the study.

The undersigned hereby agree to these terms and conditions governing the handling of confidential information, and commits him /her to these terms and conditions:

Signature of the Principal Investig	ator Date (I	/ / DD/MM/YYYY)
	nembers (Co-investigator(s)/Data .	·
Print Name	Signature	Date Signed (DD/MM/YYYY)
SECTION 6:		
DIVISION/DEPARTMENT/PRO I have reviewed this proposal and a		L:
Division/Department/Program M	·	Date:
Signature: Department:		/ / (DD/MM/YYYY)
SECTION 7: REB Office Use On	ly REB#	
□ Approved □	Not Approved □ Pe	ending with revisions
Comments:		
Signature of REB Chair or Designate:	Print Name:	Date: / / (DD/MM/YYYY)
SECTION 8: Health Information N	Management (HIM) Office Use O	nly
□ Approved □	Not Approved	
Comments:		
Signature of Manager, HIM, Privacy and Risk Management	Print Name:	Date: / / (DD/MM/YYYY)